Bone Disorders is an indication for drug development with over 230 pipeline drugs currently active. According to GlobalData, preregistered drugs for Bone Disorders have a 63.64% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Bone Disorders compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Bone Disorders overview

Bones tend to become weaker or loosen their strength as aging. Many bone diseases affect its function ranging from bone weakening to breakage of bones. Low bone density or osteoporosis, bone cancers, bone infections, Paget’s disease, osteomyelitis, osteopenia, rickets, etc. Frequent injuries, falls, aging, underlying diseases, autoimmune factors, vitamin D or low calcium levels are some of the etiological factors. These diseases are diagnosed by X-rays, bone biopsy, calcium blood test, and alkaline phosphatase levels. Vitamin- D supplements, life style changes, and other non-pharmacological parameters are practiced for treating these conditions and surgery in complicated cases.

For a complete picture of PTSR and LoA scores for drugs in Bone Disorders, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.